GlassScriptPhysician profile
Paul Douglas Orange
NPI 1275522914
$8,475.55
in general payments reported to CMS, 2019-2025
35 companies · $2,483 in 2025
The $2,483 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $207 · 2021: $1,128 · 2022: $748 · 2023: $1,510 · 2024: $2,400 · 2025: $2,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,298 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,298.38 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,712.20 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,325.36 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $746.32 | 2021-2025 | |
| Glaxosmithkline, LLC. | $694.84 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $653.07 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $521.34 | 2021-2025 | |
| Daiichi Sankyo INC. | $401.72 | 2021-2024 | Injectafer |
| Phathom Pharmaceuticals, INC. | $381.08 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.60 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $186.72 | 2023-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $154.11 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $153.69 | 2024-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $148.43 | 2025 | Jynarque, Rexulti |
| Abbott Laboratories | $132.27 | 2023-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.61 | 2021-2025 | Xifaxan, Trulance |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $110.94 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $95.39 | 2021-2025 | Eliquis, Camzyos |
| Corcept Therapeutics | $85.90 | 2023 | Korlym |
| Exact Sciences Corporation | $69.22 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $62.76 | 2021-2023 | Xarelto |
| Cequr Corporation | $62.65 | 2025 | Cequr Simplicity |
| Amarin Pharma, INC. | $57.11 | 2020-2021 | |
| Axsome Therapeutics, INC. | $56.66 | 2025 | Symbravo |
| Sanofi-Aventis U.S. LLC | $47.32 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $43.80 | 2025 | Euflexxa |
| Sanofi Pasteur INC. | $33.36 | 2022 | |
| Amgen INC. | $30.26 | 2024 | Repatha, Otezla |
| Xeris Pharmaceuticals, INC. | $30.12 | 2022-2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $28.35 | 2021-2024 | Capvaxive, Gardasil 9, Vaxelis |
| Takeda Pharmaceuticals U.S.A., INC. | $26.80 | 2020-2024 | Trintellix |
| Opko Pharmaceuticals, LLC | $24.88 | 2021 | |
| Impulse Dynamics (USA) INC. | $22.76 | 2025 | Optimizer |
| Averitas Pharma INC. | $22.06 | 2025 | Qutenza |
| Inspire Medical Systems, INC. | $21.41 | 2025 | Inspire |
| Bioventus LLC | $13.44 | 2024 | Durolane |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Orange listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.